FAM64A regulates the malignant phenotype and tumor microenvironment of non-small cell lung cancer by activating the JAK/STAT3/PDL1 axis
Journal of Molecular Histology · 2025
DOI: 10.1007/s10735-024-10339-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Histology, 2025. Verfasst von Shuo Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, Nanning, Guangxi Zhuang Au…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, STAT3 Transcription Factor, Lung Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) is a life-threatening disease that still lacks effective targeted treatment. Family with sequence similarity 64, member A (FAM64A) is dysregulated in different malignancies and participates in the cancer progression. To address the role of FAM64A in NSCLC. The FAM64A expression was detected by reverse transcription quantitative polymerase chain reaction and western blotting. Short-hairpin RNAs (shRNAs) against FAM64A were transfected into A549 and H460 cells. The role of FAM64A in vitro was evaluated by cell counting kit-8, transwell, enzyme-linked immunosorbent assay, immunofluorescence and western blotting. In vivo role of FAM64A was addressed in xenografted mice using immunohistochemistry and western blotting. FAM64A was upregulated in NSCLC that predicted a dismal prognosis for NSCLC patients. Knockdown of FAM64A diminished cell viability, invaded cell numbers, the Vimentin expression and the concentrations of TGF-β and IL-10, but fostered the E-cadherin expression and the concentrations of IL-2 and IFN-γ in NSCLC cells. Mechanistically, silencing of FAM64A declined the expression of JAK/STAT3/PD-L1 pathway, which was restored with the application of RO8191, an activator of JAK/STAT3 pathway. The inhibitory role of FAM64A knockdown in NSCLC cell proliferation, invasion, EMT and immune escape was inverted by the management of RO8191. In vivo, knockdown of FAM64A reduced tumor size and weight, the level of Vimentin and PD-L1, and the expression of JAK/STAT3/PD-L1 pathway, but enhanced the IFN-γ level. Upregulation of FAM64A promoted proliferation, invasion, EMT and immune escape through activating JAK/STAT3/PD-L1 axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
- Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
- Department of Cardiac Surgery, Liuzhou People's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, 545006, China.
- Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China. yybhjh112233@gmail.com.
Zitieren
APA
Shi, S., Han, J., Wu, Q., Zhong, H., Lei, B., & Yan, Y. (2025). FAM64A regulates the malignant phenotype and tumor microenvironment of non-small cell lung cancer by activating the JAK/STAT3/PDL1 axis. Journal of Molecular Histology. https://doi.org/10.1007/s10735-024-10339-6
Vancouver
Shi S, Han J, Wu Q, Zhong H, Lei B, Yan Y. FAM64A regulates the malignant phenotype and tumor microenvironment of non-small cell lung cancer by activating the JAK/STAT3/PDL1 axis. Journal of Molecular Histology. 2025. doi:10.1007/s10735-024-10339-6
BibTeX
@article{Shi2025,
author = {Shi, Shuo and Han, Jiahui and Wu, Qianbiao and Zhong, Haoqiu and Lei, Binfeng and Yan, Yibo},
title = {FAM64A regulates the malignant phenotype and tumor microenvironment of non-small cell lung cancer by activating the JAK/STAT3/PDL1 axis},
journal = {Journal of Molecular Histology},
year = {2025},
doi = {10.1007/s10735-024-10339-6}
}
EUVIMED